Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report

Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report

Abstract Background Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) developed for treatment of patients with chronic myeloid leukemia (CML). The drug has been shown to act as a potent multikinase inhibitor by blocking not only the BCR-ABL1 gene sequence but also the SRC kinase famil...

Full description

Bibliographic Details
Main Authors: Naoki Oshima, Yoshiyuki Mishima, Kotaro Shibagaki, Kousaku Kawashima, Norihisa Ishimura, Fumiyoshi Ikejiri, Chie Onishi, Takahiro Okada, Masaya Inoue, Ichiro Moriyama, Junji Suzumiya, Yoshikazu Kinoshita, Shunji Ishihara
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Gastroenterology
Subjects:
Chronic myeloid leukemia
Dasatinib
Tyrosine kinase inhibitor
Colitis
Gene expression analysis
Case report
Online Access:https://doi.org/10.1186/s12876-020-01584-6

Internet

https://doi.org/10.1186/s12876-020-01584-6

Similar Items